Central liver toxicity after SBRT: An expanded analysis and predictive nomogram.
CONCLUSION: SBRT doses to the cHBT are associated with occurrence of HBT only in PLC patients. Limiting the dose to the cHBT to VBED1040<37cc and VBED1030<45cc when treating PLC patients with SBRT may reduce the risk of HBT.
PMID: 27865544 [PubMed - as supplied by publisher]
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - Category: Radiology Authors: Toesca DA, Osmundson EC, Eyben RV, Shaffer JL, Koong AC, Chang DT Tags: Radiother Oncol Source Type: research
More News: Bile Duct Cancer | Cancer | Cancer & Oncology | Carcinoma | Cholangiocarcinoma | Hepatocellular Carcinoma | Liver | Liver Cancer | Radiation Therapy | Radiology | Toxicology | Urology & Nephrology